Molecular dynamics study of carbon nanotube as a potential dual-functional inhibitor of HIV-1 integrase

Biochemical and Biophysical Research Communications

Volumn 436, Issue 4, 2013, Pages 650-654

  Zhang, Zhishun ^a   Wang, Bingqiang ^b   Wan, Bo ^a   Yu, Long ^a   Huang, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b BGI SHENZHEN   (China)

Author keywords

Carbon nanotube; Drug delivery; HIV 1 integrase; Integrase inhibitor; Molecular dynamics simulation

Indexed keywords

CARBON NANOTUBE; INTEGRASE; INTEGRASE INHIBITOR; TRYPTOPHAN; VIRUS DNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION;

CARBON NANOTUBE; DRUG DELIVERY; HIV-1 INTEGRASE; INTEGRASE INHIBITOR; MOLECULAR DYNAMICS SIMULATION;

HIV INTEGRASE INHIBITORS; HIV-1; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; NANOTUBES, CARBON;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84880036240     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.009     Document Type: Article

References (34)

1. Pommier Y., Johnson A.A., Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug. Discov. 2005, 4:236-248.
2. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D., Gonzalez C.J., Chen J., Harvey C.M., Isaacs R.D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269.
3. Schames J.R., Henchman R.H., Siegel J.S., Sotriffer C.A., Ni H., McCammon J.A. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 2004, 47:1879-1881.
4. Sato M., Motomura T., Aramaki H., Matsuda T., Yamashita M., Ito Y., Kawakami H., Matsuzaki Y., Watanabe W., Yamataka K., Ikeda S., Kodama E., Matsuoka M., Shinkai H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49:1506-1508.
5. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., Kano M., Ikeda S., Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82:764-774.
6. Huang M., Grant G.H., Richards W.G. Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study. J. Mol. Graph. Model. 2011, 29:956-964.
7. Chen A., Weber I.T., Harrison R.W., Leis J. Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat ends. J. Biol. Chem. 2006, 281:4173-4182.
8. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Meibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Teppler H., Nguyen B.Y. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:355-365.
9. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51:5843-5855.
10. Friedman S.H., Ganapathi P.S., Rubin Y., Kenyon G.L. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation. J. Med. Chem. 1998, 41:2424-2429.
11. Bosi S., Da Ros T., Spalluto G., Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur. J. Med. Chem. 2003, 38:913-923.
12. Schinazi R.F., Sijbesma R., Srdanov G., Hill C.L., Wudl F. Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene. Antimicrob. Agents Chemother. 1993, 37:1707-1710.
13. Benyamini H., Shulman-Peleg A., Wolfson H.J., Belgorodsky B., Fadeev L., Gozin M. Interaction of c(60)-fullerene and carboxyfullerene with proteins: docking and binding site alignment. Bioconjug. Chem. 2006, 17:378-386.
14. Gupta S.K., Baweja L., Gurbani D., Pandey A.K., Dhawan A. Interaction of C60 fullerene with the proteins involved in DNA mismatch repair pathway. J. Biomed. Nanotechnol. 2011, 7:179-180.
15. Alian A., Griner S.L., Chiang V., Tsiang M., Jones G., Birkus G., Geleziunas R., Leavitt A.D., Stroud R.M. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc. Natl. Acad. Sci. USA 2009, 106:8192-8197.
16. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., Sugimoto H., Endo T., Murai H., Davies D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96:13040-13043.
17. Eswar N., Webb B., Marti-Renom M.A., Madhusudhan M.S., Eramian D., Shen M.Y., Pieper U., Sali A. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics 2006, 15:5.6.1-5.6.30.
18. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234:779-815.
19. Ramachandran G.N., Sasisekharan V. Conformation of polypeptides and proteins. Adv. Protein Chem. 1968, 23:283-438.
20. Pronk S., Pall S., Schulz R., Larsson P., Bjelkmar P., Apostolov R., Shirts M.R., Smith J.C., Kasson P.M., van der Spoel D., Hess B., Lindahl E. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013, 29:845-854.
21. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006, 65:712-725.
22. Feller S.E., Yin D., Pastor R.W., MacKerell A.D. Molecular dynamics simulation of unsaturated lipid bilayers at low hydration: parameterization and comparison with diffraction studies. Biophys. J. 1997, 73:2269-2279.
23. Alexiadis A., Kassinos S. Molecular simulation of water in carbon nanotubes. Chem. Rev. 2008, 108:5014-5034.
24. Perez A., Rubio A. A molecular dynamics study of water nucleation using the TIP4P/2005 model. J. Chem. Phys. 2011, 135:244505.
25. Ye H., Zhang H., Zhang Z., Zheng Y. Size and temperature effects on the viscosity of water inside carbon nanotubes. Nanoscale Res. Lett. 2011, 6:87.
26. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996, 14(33-38):27-38.
27. Fitzkee N.C., Torchia D.A., Bax A. Measuring rapid hydrogen exchange in the homodimeric 36kDa HIV-1 integrase catalytic core domain. Protein Sci. 2011, 20:500-512.
28. Xie H., Becraft E.J., Baughman R.H., Dalton A.B., Dieckmann G.R. Ranking the affinity of aromatic residues for carbon nanotubes by using designed surfactant peptides. J. Pept. Sci. 2008, 14:139-151.
29. Bomboi F., Bonincontro A., La Mesa C., Tardani F. Interactions between single-walled carbon nanotubes and lysozyme. J. Colloid Interface Sci. 2011, 355:342-347.
30. Chen J.C., Krucinski J., Miercke L.J., Finer-Moore J.S., Tang A.H., Leavitt A.D., Stroud R.M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA 2000, 97:8233-8238.
31. Madani S.Y., Naderi N., Dissanayake O., Tan A., Seifalian A.M. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int. J. Nanomed. 2011, 6:2963-2979.
32. Chaban V.V., Prezhdo O.V. Water boiling inside carbon nanotubes: toward efficient drug release. ACS Nano 2011, 5:5647-5655.
33. Reinke R.A., Lee D.J., McDougall B.R., King P.J., Victoria J., Mao Y., Lei X., Reinecke M.G., Robinson W.E. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro. Virology 2004, 326:203-219.
34. Zhao H., Neamati N., Hong H., Mazumder A., Wang S., Sunder S., Milne G.W., Pommier Y., Burke T.R. Coumarin-based inhibitors of HIV integrase. J. Med. Chem. 1997, 40:242-249.